One-Stop Solution for VHH Antibody Development

Creative Biolabs has been a long-term expert in the field of single domain antibody (also known as VHH antibody) development. Based on our advanced technology platforms and extensive experience, we have won a good reputation for successfully accomplishing numerous challenging VHH development projects. Currently, our seasoned scientists have set up a series of one-stop procedures which can assist your VHH antibody development with the highest efficiency and the best quality.

High Throughput Procedure for Novel VHH Development

Along with over a decade of extensive experience in antibody development, Creative Biolabs can develop novel VHH to meet our clients' various project requirements. From the target identification to the final VHH antibody production, our one-stop solution can offer a series of pathways to achieve the project goals, which can free up your valuable time and effort on the innovative side of the project.

Typical Pathway for Target-specific VHH Development

Applications of VHH Antibodies

In terms of the unique properties of small size, high stability, and outgoing solubility, single domain antibody enables researchers and scientists to advance in a variety of fields, which including but not limited to:

Features of One-Stop VHH Antibody Development

Creative Biolabs has long-term devoted to the development and application of sdAbs. Our scientists are confident in offering the best and most suitable solution for our customers all over the world. If you are considering developing novel sdAbs against the target of interest, please do not hesitate to contact us for more details.

Published Data

A Single Domain Antibody to Detect and Neutralize Toxic Aβ₄₂ Oligomers

The article highlights significant progress in Alzheimer's disease research through the use of a single-domain antibody (sdAb), named DesAb-O, which selectively detects and neutralizes toxic Aβ₄₂ oligomers in cerebrospinal fluid (CSF). DesAb-O shows remarkable specificity for Aβ₄₂ oligomers compared to other amyloid forms, demonstrating a potent ability to identify and counteract these neurotoxic aggregates both in vitro and in neuronal cell cultures. This breakthrough offers dual benefits: enhancing early Alzheimer's diagnosis by pinpointing specific biomarkers in CSF, and potentially developing new therapeutic strategies targeting the toxic oligomers associated with disease progression. By mitigating the effects of these oligomers, DesAb-O could significantly impact the treatment and management of Alzheimer's disease, marking a promising step forward in the fight against this debilitating condition.

FAQ

1. What is a single domain antibody (sdAb)?

A single domain antibody (sdAb) is the smallest functional fragment of an antibody, consisting only of a single monomeric variable antibody domain. Unlike conventional antibodies, which are composed of both heavy and light chains, sdAbs lack the light chains and the constant regions, making them much smaller and more versatile.

2. How are sdAbs different from conventional antibodies?

Single domain antibodies offer several advantages over traditional antibodies due to their small size, robust structure, and high solubility. These attributes allow sdAbs to bind to epitopes that are inaccessible to conventional antibodies, providing enhanced tissue penetration and stability under extreme conditions, such as high temperatures or denaturing environments.

3. What are the primary sources of sdAbs?

Single domain antibodies are primarily derived from the heavy-chain-only antibodies found in camelids, such as llamas and camels, or from cartilaginous fishes like sharks. These organisms produce antibodies that naturally lack light chains, which have been adapted for therapeutic and diagnostic applications in humans.

4. What are the applications of sdAbs in medicine?

Single domain antibodies are used in various medical applications including as therapeutic agents in cancer, infectious diseases, and inflammatory disorders. They are also employed in diagnostic assays due to their ability to bind specifically to small and cryptic antigens, enhancing the sensitivity and specificity of these tests.

5. What makes sdAbs ideal for therapeutic use?

The small size and unique structure of sdAbs allow for rapid tissue penetration and fast clearance from the bloodstream, which is beneficial for reducing systemic toxicity. Their ability to remain stable under harsh conditions also makes them suitable for oral administration and topical applications, expanding their use beyond injectable forms.

6. How are sdAbs developed?

Single domain antibodies are typically generated through immunization of camelids or sharks and subsequent recovery of the variable domains from the immune cells. Alternatively, phage display libraries can be constructed to screen for sdAbs that bind with high affinity to desired antigens, allowing for the selection of candidates without the need for animal immunization.

7. What is the role of sdAbs in targeted drug delivery?

Single domain antibodies can be conjugated to drugs, toxins, or other therapeutic agents to form targeted delivery systems. Their precise binding to specific cellular targets allows for the direct delivery of the therapeutic agent to diseased cells, minimizing the impact on healthy tissues and reducing side effects.

8. What future advancements are expected in sdAb technology?

Future advancements in single domain antibody technology are likely to focus on improving their pharmacokinetics, reducing immunogenicity, and enhancing their therapeutic index.

Resources